1 medications are best known for their use in obesity and diabetes treatment, but new research suggests they may have potential in cancer prevention
As multiple studies presented at the American Society of Clinical Oncology’s annual meeting linked GLP-1 drugs to lower rates of breast cancer, better survival outcomes when combined with standard breast cancer treatment, and decreased odds of the cancer spreading in several major tumor types
While the findings are still early, they could inspire further research to determine if GLP-1s’ benefits could extend into the biology of cancer itself
However, I spoke with several medical experts who view these findings as a signal – not a reason to prescribe GLP-1s for cancer prevention without additional evidence
“These findings are raising important questions, but they should not be interpreted to mean that GLP-1 medications prevent or treat cancer,” said Dr. Monique Gary, a breast surgical oncologist in the St. Luke’s University Health Network
“These drugs are not approved for cancer treatment, they come with their own risks and considerations, and we still have much to learn about what may be driving the associations we’re seeing,” Gary told FI
Though GLP-1s were initially developed to treat type 2 diabetes, they’re widely used for weight management today, as they mimic a hormone that regulates blood sugar and appetite
Researchers are now studying whether their impact on weight, inflammation, and other metabolic pathways could affect cancer outcomes, given that excess weight – especially post-menopause – is known to increase breast cancer risk
One retrospective analysis of 110,000 women ages 45-80 found that those taking GLP-1s were 30% less likely to develop breast cancer than those who didn’t, while another study of 27,000 breast cancer patients found that adding these drugs to standard cancer treatment was associated with a 30% lower death risk
Meanwhile, a third study of 12,000 patients with breast, lung, bowel, or liver cancer found that individuals taking weight-loss drugs were 38-50% less likely to develop stage-four forms of their respective diseases than those who weren’t
This consistency across studies has caught clinicians’ attention, though it’s important to remember perhaps the most important research tenet when considering these findings: that correlation does not equal causation
Dr. Andrew Shapiro, a board-certified surgeon and Medical Director of the Comprehensive Breast Center at Wellington Regional Medical Center believes the research question has become less about if there’s a signal and more about what it means
“We are seeing enough consistency across studies that I suspect we will ultimately identify a meaningful role for GLP-1 therapies somewhere in the breast cancer continuum. The challenge is defining where they fit, which patients benefit most, and whether the effect is related to weight loss, metabolic health, inflammation, direct biologic effects, or a combination of factors,” he told FI
For now, Shapiro says he’d be comfortable recommending GLP-1s to patients already facing obesity, diabetes, and/or other metabolic risk factors – but not specifically as a breast cancer prevention strategy just yet.
While some experts believe the cancer-related benefits are largely tied to weight loss, which can reduce cancer risk on its own, others suspect GLP-1s may have additional effects like lowering chronic inflammation or impacting tumor-related pathways
“A central question arising from this research is the ‘how’ and ‘why.’ We know obesity is a significant risk factor for cancer, so the substantial weight loss induced by these drugs is undoubtedly a major contributor to the reduced risk,” said Dr. Deena Graham, a breast medical oncologist at John Theurer Cancer Center – Hackensack University Medical Center
“However, the data also suggests that the drugs’ anti-inflammatory properties and other metabolic effects might be inhibiting tumor growth directly, independent of weight loss,” Graham told FI
Dr. Michael Shockley, a board-certified surgeon at Advanced Surgical Physicians, also highlighted weight loss and inflammation as likely drivers but remains open to the possibility that GLP-1s could help for other reasons
“This new data should be considered in this individualized approach and discussion, but I do not think a causative relationship has been established where the overall guidelines to managing these patients should be changed,” Shockley told FI
At the moment, these studies appear to have raised more questions than they’ve answered
However, they demonstrate that GLP-1s are increasingly solidifying their place in a broader conversation, which may go beyond obesity and diabetes to encompass both cancer prevention and survival. Only time – and additional evidence – will tell
Food for Thought Leadership
Food retail is undergoing a fundamental transformation, and few people have a better vantage point than the SupermarketGuru Phil Lempert. In this episode ofFood for Thought Leadership, Lempert joins FI’s Chris Campbell to discuss the forces reshaping grocery, from inflation and private label growth to changing consumer expectations around health, wellness, and transparency
